Makale
Kısa Makale
Uluslararası
2024
Pembrolizumab in HER2-Positive Gastric Cancer
NEW ENGLAND JOURNAL OF MEDICINE
01.09.2024
Özet
Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.
Atıf için künye
Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez, P., Wyrwicz, L. S., Shen, L., Ostapenko, Y., Bilici, M., Chung, H. C., Shitara, K., Qin, S., Van Cutsem, E., Tabernero, J., Luo, S., Mahave, M., Tang, Y., … Rha, S. Y. (2024). Pembrolizumab in HER2-Positive Gastric Cancer. NEW ENGLAND JOURNAL OF MEDICINE. https://doi.org/10.1056/nejmc2408121
BibTeX
@article{janjigian2024-228388,
author = {Janjigian, Yelena Y. and Kawazoe, Akihito and Bai, Yuxian and Xu, Jianming and Lonardi, Sara and Metges, Jean Phillipe and Yanez, Patricio and Wyrwicz, Lucjan S. and Shen, Lin and Ostapenko, Yuriy and Bilici, Mehmet and Chung, Hyun Cheol and Shitara, Kohei and Qin, Shukui and Van Cutsem, Eric and Tabernero, Josep and Luo, Suxia and Mahave, Mauricio and Tang, Yong and Lowery, Maeve and Monteiro, Maria M. F. and Xu, Linzhi and Shih, Chie-Schin and Sharan, Kanu P. and Bhagia, Pooja and Rha, Sun Young},
title = {Pembrolizumab in HER2-Positive Gastric Cancer},
journal = {NEW ENGLAND JOURNAL OF MEDICINE},
year = {2024},
issn = {0028-4793},
doi = {10.1056/nejmc2408121},
url = {https://akademik.atauni.edu.tr/yayinlar/228388-pembrolizumab-in-her2-positive-gastric-cancer}
}